These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 21351274

  • 1. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2010 Dec 15; 127(12):2959-64. PubMed ID: 21351274
    [Abstract] [Full Text] [Related]

  • 2. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH.
    Cancer Res; 2009 Dec 01; 69(23):8996-9002. PubMed ID: 19920203
    [Abstract] [Full Text] [Related]

  • 3. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Mol Cancer Ther; 2008 Aug 01; 7(8):2280-7. PubMed ID: 18723475
    [Abstract] [Full Text] [Related]

  • 4. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
    van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH.
    Br J Pharmacol; 2010 Jul 01; 160(5):1224-33. PubMed ID: 20590614
    [Abstract] [Full Text] [Related]

  • 5. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 6. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
    Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Invest New Drugs; 2014 Dec 15; 32(6):1083-95. PubMed ID: 25078948
    [Abstract] [Full Text] [Related]

  • 7. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O.
    Cancer Res; 2002 Nov 01; 62(21):6158-64. PubMed ID: 12414642
    [Abstract] [Full Text] [Related]

  • 8. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
    Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2014 Mar 01; 85(3):520-30. PubMed ID: 24334255
    [Abstract] [Full Text] [Related]

  • 9. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 10. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW.
    Drug Metab Dispos; 2012 Sep 01; 40(9):1825-33. PubMed ID: 22711747
    [Abstract] [Full Text] [Related]

  • 11. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJ, Tan EH, Lim WT, Chowbay B.
    Cancer Chemother Pharmacol; 2011 Jun 01; 67(6):1471-8. PubMed ID: 21468756
    [Abstract] [Full Text] [Related]

  • 12. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O.
    Eur J Cancer; 2013 May 01; 49(8):2059-64. PubMed ID: 23422148
    [Abstract] [Full Text] [Related]

  • 13. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
    Tang SC, Sparidans RW, Cheung KL, Fukami T, Durmus S, Wagenaar E, Yokoi T, van Vlijmen BJ, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2014 Jun 15; 20(12):3133-45. PubMed ID: 24727322
    [Abstract] [Full Text] [Related]

  • 14. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Mol Pharm; 2018 Nov 05; 15(11):5124-5134. PubMed ID: 30247919
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2019 Feb 10; 556():172-180. PubMed ID: 30553002
    [Abstract] [Full Text] [Related]

  • 16. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2018 Oct 15; 143(8):2029-2038. PubMed ID: 29744867
    [Abstract] [Full Text] [Related]

  • 17. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
    Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH.
    Drug Metab Dispos; 2011 Aug 15; 39(8):1338-44. PubMed ID: 21566011
    [Abstract] [Full Text] [Related]

  • 18. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
    Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6125-32. PubMed ID: 17062689
    [Abstract] [Full Text] [Related]

  • 19. Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.
    Hudachek SF, Gustafson DL.
    J Pharmacokinet Pharmacodyn; 2013 Aug 15; 40(4):437-49. PubMed ID: 23616082
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 Jan 05; 573():118842. PubMed ID: 31759109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.